You are here: Industry Insights > Exonate

News List

Exonate launches diabetic macular oedema trial pharmatimes
February 04, 2021
Cambridge, UK-based Exonate has dose the first patient with its lead compound – EXN 407 – in a Phase Ib/II clinical trial investigating the drug in volunteers with centre-involved diabetic macular oedema (CI-DMO).
Exonate Announces Collaboration With Janssen to Develop a New Eye Drop for the Treatment of Retinal Vascular Diseases Including Wet Age-related Macular degeneration (AMD) and Diabetic Macular Oedema (DMO) prnasia
January 13, 2020
Exonate, an early stage biotechnology company, announced today that it has entered into a strategic collaboration agreement with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Wellcome Trust grants funding to Exonate to develop wet AMD pharmaceutical-technology
February 09, 2017
UK-based biotechnology company Exonate has secured a Seeding Drug Discovery fund from Wellcome Trust to continue development of an eye-drop treatment for wet age-related macular degeneration (wet AMD).